Praxis Precision Medicines, Inc. (PRAX)

NASDAQ:
PRAX
| Latest update: Mar 9, 2026, 6:38 PM

Price Chart

$306.31

1.19%
(1 month)

Top Shareholders

Janus Henderson Group Plc
12.96%
BlackRock, Inc.
8.31%
Perceptive Advisors LLC
7.98%
The Vanguard Group, Inc.
5.84%
FMR LLC
5.43%
Allan & Gill Gray Foundation
5.02%
Baker Bros. Advisors LP
4.50%
T. Rowe Price Group, Inc.
4.25%

Sentiment for PRAX

News
Social

Buzz Talk for PRAX

Today

Social Media

General

Stock events for Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines' stock has experienced significant volatility, with a 778.82% increase over the past year as of March 4, 2026. Key events include a 1-for-15 reverse stock split on November 29, 2023, Breakthrough Designation from the FDA for Ulixacaltamide, positive trial results for an epilepsy drug, NDA submissions for Ulixacaltamide and Relutrigine, Q4 2025 earnings reporting ($3.50) earnings per share, and Wolfe Research initiating coverage with an "Outperform" recommendation.

Demand Seasonality affecting Praxis Precision Medicines, Inc.’s stock price

There is no explicit information available regarding demand seasonality for Praxis Precision Medicines, Inc.'s products or services. Demand is likely driven by disease prevalence, unmet medical needs, clinical efficacy, regulatory approvals, and market access, rather than seasonal fluctuations.

Overview of Praxis Precision Medicines, Inc.’s business

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders by translating genetic insights into treatments for conditions characterized by neuronal excitation-inhibition imbalance. The company operates within the Healthcare sector, utilizing its Cerebrum and Solidus platforms to develop neurological disorder therapies. Praxis has a diversified CNS portfolio with clinical-stage product candidates targeting movement disorders and epilepsy, including Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen.

PRAX’s Geographic footprint

Praxis Precision Medicines, Inc. is headquartered in Boston, Massachusetts, United States, and its development activities for CNS disorders are conducted in the United States.

PRAX Corporate Image Assessment

Praxis Precision Medicines generally holds a positive brand reputation, with a consensus rating of "Moderate Buy" or "Buy" from analysts. The FDA's Breakthrough Designation for Ulixacaltamide, positive clinical trial results, and analyst confidence contribute to its strong reputation. While the company's stock has been volatile and it reported a wider net loss in Q4 2025, these financial aspects are more related to investor sentiment and financial performance rather than a direct impact on the scientific or ethical brand reputation.

Ownership

The ownership structure of Praxis Precision Medicines stock includes institutional investors (approximately 18.66% to 30.74%), insiders (approximately 18.01%), and public companies and individual/retail investors. Major institutional holders include Janus Henderson Group PLC, BlackRock, Inc., and Perceptive Advisors LLC. Bsof Parallel Master Fund LP is a significant individual shareholder. Steven A. Cohen is mentioned as owning the most shares of Praxis Precision Medicines.

FAQ

What is the current stock price of Praxis Precision Medicines, Inc.?

As of the latest update, Praxis Precision Medicines, Inc.'s stock is trading at $306.31 per share.

What’s happening with Praxis Precision Medicines, Inc. stock today?

Today, Praxis Precision Medicines, Inc. stock is down by -1.19%, possibly due to news.

What is the market sentiment around Praxis Precision Medicines, Inc. stock?

Current sentiment around Praxis Precision Medicines, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Praxis Precision Medicines, Inc.'s stock price growing?

Over the past month, Praxis Precision Medicines, Inc.'s stock price has decreased by -1.19%.

How can I buy Praxis Precision Medicines, Inc. stock?

You can buy Praxis Precision Medicines, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol PRAX

Who are the major shareholders of Praxis Precision Medicines, Inc. stock?

Major shareholders of Praxis Precision Medicines, Inc. include institutions such as Janus Henderson Group Plc (12.96%), BlackRock, Inc. (8.31%), Perceptive Advisors LLC (7.98%) ... , according to the latest filings.